Catalent Inc CTLT

Catalent, Inc. develops and manufactures solutions for drugs; protein, cell and gene therapy; consumer health products; and biologics. Operating internationally, the company typically has over 1,000 products in development at any given time. Catalent was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Catalent operates through four segments, including Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. Catalent manufactures over 70 billion doses each year for over 1,000 customers around the world. The company employs approximately 15,000 people, including around 2,400 scientists and technicians. Catalent has sites in Asia Pacific, Europe, Latin America, and North America, including manufacturing, development, packaging, storage, and design facilities.

Available on the NYSE, Catalent stock is listed under the ticker CTLT. In June 2021, Catalent acquired RheinCell Therapeutics GmbH. This acquisition is expected to strengthen Catalent's cell and gene therapy business. In July 2021, the company announced plans for a $100m expansion of its vaccine plant in Anagni, Italy which, as of December 2021, was being used to fill vials for Johnson & Johnson and AstraZeneca. In August 2021, Catalent announced reaching an agreement to acquire Bettera Holdings, LLC, a manufacturer of nutritional supplements, for $1bn.

Track the share price of CTLT by adding it to your eToro watchlist.